Cadazolid

Summary

Cadazolid (CHEMBL3707376) is a phase-3 clinical-stage small molecule; indicated across 1 condition including clostridium infectious disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Clinical trials: 5
• Chemistry: 585.6 Da · C29H29F2N3O8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707376
Name	Cadazolid
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	44242317
Molecular formula	C29H29F2N3O8
Molecular weight	585.6
InChIKey	XWFCFMXQTBGXQW-GOSISDBHSA-N

SMILES: C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCC(CC4)(COC5=C(C=C(C=C5)N6C[C@@H](OC6=O)CO)F)O)F)C(=O)O

IUPAC name: 1-cyclopropyl-6-fluoro-7-[4-[[2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenoxy]methyl]-4-hydroxypiperidin-1-yl]-4-oxoquinoline-3-carboxylic acid

Also known as: ACT-179811, Cadazolid, CADAZOLID

Patent coverage: 40 distinct patent families (115 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 85 (74%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Clostridium infectious disease	3	MONDO:0024388	EFO:0009130

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2/PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01983683	PHASE3	COMPLETED	Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea
NCT01987895	PHASE3	COMPLETED	Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea
NCT03105479	PHASE2/PHASE3	TERMINATED	Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)
NCT01222702	PHASE2	COMPLETED	Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)
NCT02053181	PHASE1	COMPLETED	Study to Investigate the Pharmacokinetics and Safety of Cadazolid in Patients With Clostridium Difficile Infection

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).